Lower chemo dose may prevent transplant complications
NCT ID NCT07319000
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a low dose of the drug cyclophosphamide, given after a stem cell transplant, can prevent graft-versus-host disease (GVHD) — a common and serious complication where donor cells attack the patient's body. The trial involved 35 adults with various blood diseases who received a transplant from a related donor. The goal was to see if the low dose could keep severe GVHD rates low while helping blood cells recover faster.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cyclophosphamide
- What this could lead to
- If it works, this could offer a safer way to prevent graft-versus-host disease after stem cell transplants, with faster blood cell recovery.
- What could go wrong
- This is a small, early-phase trial with only 35 participants. The low dose may not be as effective as standard doses, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital Universitario de Monterrey
Monterrey, 64460, Mexico
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Can trained immune cells stop blood cancer relapse?
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Could muscle loss predict blood cancer outcomes?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a modified enzyme starve Hard-to-Treat blood cancers?